CA2506230A1 - Utilisations anti-angiogeniques d'antagonistes de il-6 - Google Patents

Utilisations anti-angiogeniques d'antagonistes de il-6 Download PDF

Info

Publication number
CA2506230A1
CA2506230A1 CA002506230A CA2506230A CA2506230A1 CA 2506230 A1 CA2506230 A1 CA 2506230A1 CA 002506230 A CA002506230 A CA 002506230A CA 2506230 A CA2506230 A CA 2506230A CA 2506230 A1 CA2506230 A1 CA 2506230A1
Authority
CA
Canada
Prior art keywords
angiogenesis
mammal
monoclonal antibody
antibody
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002506230A
Other languages
English (en)
Inventor
Mohit Trikha
Zhao Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2506230A1 publication Critical patent/CA2506230A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un procédé d'utilisation d'antagonistes de IL-6 pour traiter les processus pathologiques associés à des maladies prolifératives, notamment le cancer. Le procédé consiste à inhiber ou à empêcher spécifiquement la capacité d'un nouveau tissu à développer une réserve sanguine. L'invention concerne en particulier des méthodes de traitement de telles maladies faisant appel à l'utilisation d'antagonistes de IL-6, notamment des anticorps dirigés contre IL-6, y compris des parties ou des variants spécifiés, spécifiques d'au moins une protéine d'interleukine-6 (IL-6 également connu sous le nom d'interféron .beta.2) ou un fragment de celle-ci, dans une quantité efficace pour inhiber l'angiogenèse.
CA002506230A 2002-11-15 2003-11-10 Utilisations anti-angiogeniques d'antagonistes de il-6 Abandoned CA2506230A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42690102P 2002-11-15 2002-11-15
US60/426,901 2002-11-15
PCT/US2003/035651 WO2004045507A2 (fr) 2002-11-15 2003-11-10 Utilisations anti-angiogeniques d'antagonistes de il-6

Publications (1)

Publication Number Publication Date
CA2506230A1 true CA2506230A1 (fr) 2004-06-03

Family

ID=32326451

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002506230A Abandoned CA2506230A1 (fr) 2002-11-15 2003-11-10 Utilisations anti-angiogeniques d'antagonistes de il-6

Country Status (5)

Country Link
EP (1) EP1572103A4 (fr)
JP (1) JP2006516957A (fr)
AU (1) AU2003290682A1 (fr)
CA (1) CA2506230A1 (fr)
WO (1) WO2004045507A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2866566A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un inhibiteur de la secretion d'il-5,il-6 et/ou il-10 pour le traitement de la rosacee
IL163856A0 (en) * 2004-09-01 2005-12-18 Applied Research Systems Use of IL-6 in vascular complications
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
EP1941908B1 (fr) 2005-10-21 2015-08-19 Chugai Seiyaku Kabushiki Kaisha Agent therapeutique pour maladie de coeur
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
DK1966244T3 (da) 2005-12-30 2012-04-23 Merck Patent Gmbh Anti-il-6-antistoffer der forebygger bindingen af il-6 sammensat af il-6ralfa til gp130
EP3135298B1 (fr) * 2006-01-27 2018-06-06 Keio University Agents thérapeutiques pour maladie associée à la neovascularisation choroïdienne
EP2025346B1 (fr) 2006-04-07 2016-08-10 Osaka University Promoteur de régénération musculaire
US7919095B2 (en) 2006-08-03 2011-04-05 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
PE20081635A1 (es) 2007-01-23 2009-01-07 Chugai Pharmaceutical Co Ltd Agentes para suprimir la reaccion de rechazo cronica
EP2174667B1 (fr) 2007-07-26 2017-01-04 Osaka University Agent pour le traitement de l'ophtalmie contenant un inhibiteur du récepteur de l'interleukine 6 en tant qu'ingrédient actif
SG188134A1 (en) * 2007-11-15 2013-03-28 Chugai Pharmaceutical Co Ltd Monoclonal antibody capable of binding to anexelekto, and use thereof
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2010133087A1 (fr) * 2009-05-18 2010-11-25 The University Of Hong Kong Compositions et procédés pour traiter une arthrite inflammatoire
SG10201404340TA (en) * 2009-07-31 2014-10-30 Shin Maeda Cancer metastasis inhibitor
ES2932398T3 (es) 2010-05-28 2023-01-18 Chugai Pharmaceutical Co Ltd Potenciador de la respuesta de las células T antitumorales
SG10201608703SA (en) * 2012-11-08 2016-12-29 Eleven Biotherapeutics Inc Il-6 antagonists and uses thereof
EP2898896A1 (fr) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents pour utilisation dans le traitement de l'inflammation de la rétine
CN106102766A (zh) * 2014-01-22 2016-11-09 皮埃尔与玛丽·居里大学 - 巴黎第六大学 用于治疗视网膜炎症的试剂
CN107249631B (zh) * 2014-11-07 2021-11-23 十一生物治疗股份有限公司 改进的il-6抗体
AU2018214554C1 (en) 2017-02-01 2022-12-15 Novo Nordisk A/S Treatment of diuretic resistance
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
JP7395479B2 (ja) 2018-01-05 2023-12-11 ノヴォ ノルディスク アー／エス 免疫抑制なしにｉｌ－６媒介性炎症を処置する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0800829B2 (fr) * 1994-12-29 2012-07-25 Chugai Seiyaku Kabushiki Kaisha Utilisation d'un anticorps pm-1 ou d'un anticorps mh 166 pour potentialiser l'effet antitumoral de la cisplatine ou de la carboplatine
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
US6531580B1 (en) * 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same

Also Published As

Publication number Publication date
WO2004045507A3 (fr) 2006-01-26
EP1572103A2 (fr) 2005-09-14
EP1572103A4 (fr) 2008-02-13
JP2006516957A (ja) 2006-07-13
AU2003290682A1 (en) 2004-06-15
WO2004045507A2 (fr) 2004-06-03

Similar Documents

Publication Publication Date Title
CA2506230A1 (fr) Utilisations anti-angiogeniques d'antagonistes de il-6
AU2004231159B8 (en) Vascular endothelial cell growth factor antagonists and uses thereof
CN1829740B (zh) 结缔组织生长因子抗体
DE60118186T2 (de) Verwendung von inhibitoren des plazenta wachstumsfactors für die behandlung einer pathologischen angiogenese, pathologischen arteriogenese, entzündung, tumorbildung und/oder gefässdurchlässigkeit (ödem)
EP0666868B2 (fr) Usage d'anticorps anti-VEGF pour le traitement du cancer
US10676527B2 (en) Methods and compositions for modulation of blood-neural barrier
BRPI0609151B1 (pt) molécula de ligação ao antígeno capaz de se ligar a plgf, usos da mesma, linhagem celular de hibridoma, composição farmacêutica e polinucleotídeo
US20090028862A1 (en) Emmprin antagonists and uses thereof
US20050100550A1 (en) Anti-angiogenic uses of IL-6 antagonists
EP2349330B1 (fr) Procédé de médiation de la réponse fibrotique
US20050031615A1 (en) Method of inhibiting tumor growth with anti-tissue factor antibodies
CA2560903A1 (fr) Utilisation d'antagonistes de l'inducteur de metalloproteinase dans la matrice extracellulaire pour le traitement de maladies associees a un angiogenese excessive
US20050214302A1 (en) Use of emmprin antagonists for the treatment of diseases associated with excessive angiogenesis
MXPA05012974A (en) Method of inhibiting tumor growth with anti-tissue factor antibodies

Legal Events

Date Code Title Description
FZDE Dead